title: Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.
abstract: Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of insulin-producing β cells by autoreactive T cells, leading to lifelong dependency on insulin therapy and increased risk of long-term cardiovascular complications. Here we take the opportunity of the 20(th) anniversary of the generation of the BDC2.5 TCR transgenic non-obese diabetic (NOD) mouse model, to provide a brief overview of the significant progress that has been made in understanding the role of T cells in the disease pathogenesis period. This included development of hundreds of reagents that block or even reverse new-onset disease by directly or indirectly controlling T cells. We also reflect on the sobering fact that none of these strategies has shown significant efficacy in clinical trials and discuss potential reasons hindering translation of the preclinical findings into successful therapeutic strategies and potential ways forward.
authors: Lourdes Ramirez, Abdel Rahim A Hamad, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
authors: Lourdes
authors: L
authors: Ramirez
authors: Abdel Rahim A
authors: AR
authors: Hamad
keywords: Anti-CD3; Autoimmune diabetes; BDC2.5 T cells; Immunosuppression; Immunotherapy; T cells
references: Cell. 1993 Sep 24;74(6):1089-100
references: 8402882
references: Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-7
references: 8278351
references: J Exp Med. 1987 Oct 1;166(4):823-32
references: 3309126
references: Diabetes. 2011 May;60(5):1370-9
references: 21525508
references: J Immunol. 2005 Jun 1;174(11):7129-40
references: 15905556
references: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2260-3
references: 8637860
references: Am J Pathol. 2007 Jul;171(1):97-106
references: 17591957
references: Jikken Dobutsu. 1980 Jan;29(1):1-13
references: 6995140
references: Diabetes. 1988 Oct;37(10):1444-8
references: 2458291
references: Annu Rev Immunol. 1995;13:179-200
references: 7612220
references: Adv Immunol. 2005;87:123-62
references: 16102573
references: Annu Rev Immunol. 2005;23:447-85
references: 15771578
references: Diabetes. 2013 Jan;62(1):9-17
references: 23258904
references: Nat Immunol. 2010 Mar;11(3):225-31
references: 20139986
references: Curr Opin Immunol. 2009 Dec;21(6):641-7
references: 19747810
references: J Immunol. 2011 Apr 1;186(7):3831-5
references: 21357258
references: Diabetes. 1996 Oct;45(10):1299-305
references: 8826963
references: J Clin Invest. 2007 Dec;117(12):3857-67
references: 18060033
references: Nature. 1995 Feb 2;373(6513):441-4
references: 7530336
references: Immunotherapy. 2010 May;2(3):289-91
references: 20635894
references: Curr Opin Endocrinol Diabetes Obes. 2011 Aug;18(4):235-40
references: 21844706
references: Nature. 2008 Oct 23;455(7216):1109-13
references: 18806780
references: Science. 2013 Mar 1;339(6123):1084-8
references: 23328391
references: Diabetes. 2006 Dec;55(12):3611-9
references: 17130511
references: J Immunol. 2000 Aug 15;165(4):1949-55
references: 10925277
references: J Immunol. 1988 Jan 1;140(1):52-8
references: 3275717
references: J Clin Invest. 2006 May;116(5):1371-81
references: 16628253
references: Nat Med. 1998 Dec;4(12):1377-82
references: 9846574